NASDAQ:DRMA

Dermata Therapeutics Q2 2025 Earnings Results & Report

Dermata Therapeutics logo
$0.57 -0.03 (-4.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+1.56%)
As of 11/17/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dermata Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$1.66 versus the -$2.90 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Dermata Therapeutics EPS Results

Actual EPS
-$1.66
Consensus EPS
-$2.90
Beat/Miss
Beat by +$1.24
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Dermata Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Dermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Dermata Therapeutics Q2 2025 Earnings FAQ

Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$1.66 per share for Q2 2025, beating the consensus estimate of -$2.90. The report was announced on Wednesday, August 13, 2025.

Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page.

Dermata Therapeutics Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on Wednesday
See More Dermata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email.

About Dermata Therapeutics

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies.

Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.

View Dermata Therapeutics Profile